1. Home
  2. LGND vs HNI Comparison

LGND vs HNI Comparison

Compare LGND & HNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • HNI
  • Stock Information
  • Founded
  • LGND 1987
  • HNI 1944
  • Country
  • LGND United States
  • HNI United States
  • Employees
  • LGND N/A
  • HNI N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • HNI Office Equipment/Supplies/Services
  • Sector
  • LGND Health Care
  • HNI Consumer Discretionary
  • Exchange
  • LGND Nasdaq
  • HNI Nasdaq
  • Market Cap
  • LGND 2.0B
  • HNI 2.0B
  • IPO Year
  • LGND 1992
  • HNI N/A
  • Fundamental
  • Price
  • LGND $114.07
  • HNI $46.40
  • Analyst Decision
  • LGND Strong Buy
  • HNI Strong Buy
  • Analyst Count
  • LGND 8
  • HNI 2
  • Target Price
  • LGND $144.71
  • HNI $66.50
  • AVG Volume (30 Days)
  • LGND 116.0K
  • HNI 267.4K
  • Earning Date
  • LGND 08-05-2025
  • HNI 07-24-2025
  • Dividend Yield
  • LGND N/A
  • HNI 2.94%
  • EPS Growth
  • LGND N/A
  • HNI 100.29
  • EPS
  • LGND N/A
  • HNI 2.80
  • Revenue
  • LGND $181,488,000.00
  • HNI $2,538,200,000.00
  • Revenue This Year
  • LGND $18.41
  • HNI $4.50
  • Revenue Next Year
  • LGND $18.87
  • HNI $3.48
  • P/E Ratio
  • LGND N/A
  • HNI $16.51
  • Revenue Growth
  • LGND 53.40
  • HNI N/A
  • 52 Week Low
  • LGND $77.53
  • HNI $39.76
  • 52 Week High
  • LGND $129.90
  • HNI $58.42
  • Technical
  • Relative Strength Index (RSI)
  • LGND 62.44
  • HNI 48.69
  • Support Level
  • LGND $111.88
  • HNI $46.26
  • Resistance Level
  • LGND $116.16
  • HNI $47.58
  • Average True Range (ATR)
  • LGND 3.58
  • HNI 0.91
  • MACD
  • LGND 0.89
  • HNI -0.20
  • Stochastic Oscillator
  • LGND 85.19
  • HNI 22.11

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About HNI HNI Corporation

HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.

Share on Social Networks: